09/678,554

-2-

5604-D1-01-SRE

This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims:

Claim 1 (previously amended) A compound having the Formula I

wherein:

 R^a , R^b , R^c are each independently C_1 - C_6 alkyl or hydrogen;

Rd, Re, Rf, and Rg are each independently C1-C6 alkyl, hydrogen, or phenyl;

 \mathbb{R}^3 is

$$-$$
(CH₂)_n $-$ phenyl,

$$-(CH_2)_n$$

$$--(CH2)n ---C1-C6 alkyl ,$$

$$--(CH_2)_n$$
 — heteroary1, or

$$--(CH2)n$$
—substituted phenyl;

$$R^2$$
 is
$$R^d$$

$$C C R^4$$

$$R^f (CH_2)_m$$

 R^4 is aryl, substituted aryl, or $C_1\text{-}C_6$ alkyl; and

each n is independently 0 to 5, m is 2 to 4 or a pharmaceutically acceptable salt or prodrug form thereof.

09/678,554

-3-

5604-D1-01-SRE

Claim 2 (previously amended) The compound of Claim 1 wherein Y is -O-.

Claim 3 (previously amended) The compound of Claim 1 wherein

Claim 4 (previously amended) The compound of Claim 1 wherein R^a is hydrogen, R^b is methyl, and R^c is hydrogen.

Claim 5 (previously amended) The compound of Claim 1 wherein

$$\mathbb{R}^3$$
 is $-(CH_2)_n$ $-o$ -benzyl

Claim 6 (previously amended) The compound of Claim 1 wherein R³

$$-(CH_2)_n$$

Claims 7 and 8 (canceled).

Claim 9 (previously amended) The compound of Claim 1 wherein

Claim 10 (previously amended) The compound of Claim 9 wherein m of

$$\frac{\overset{H}{\overset{|}{\downarrow}}}{\overset{|}{\downarrow}}_{(CH_2)_m}^{CD} \text{ or } \frac{\overset{H}{\overset{|}{\downarrow}}}{\overset{|}{\downarrow}}_{(CH_2)_m}^{CD} \text{substituted phenyl.}$$

m is 3 or 4.

09/678,554

4-

5604-D1-01-SRE

Claim 11 (previously amended) The compound of Claim 1 wherein \mathbb{R}^3 is -(CH₂)_n-C₁-C₆ alkyl.

Claim 12 (previously amended) The compound of Claim I wherein

$$R^3$$
 is $-(CH_2)$ OCH_2 -pyridyl .

Claim 13 (canceled).

Claim 14 (currently amended) The compound ex-

[\$ (R*,R*)]-[1-({2-(4-Benzylexy-phenyl)-1-[(1-phenyl-

eyclopropyl methyl)-carbamoyl] ethyl} methyl carbamoyl) 2 (3H-imidazol 4-

yl)-ethyl]-carbamic acid-benzyl ester;

 $[S-(R^*,R^*)]-[1-[(2-(4-Benzyloxy-phenyl)-1-\{[1-(2-fluoro-phenyl)-1-(2-fluoro-phenyl$

cyclopropylmethyl]-carbamoyl}ethyl)-methyl-carbamoyl]-2-(3H-imidazol-

4-yl)-ethyl]-carbamic acid benzyl ester ; and

[S-(R*,R*)] [1-{[2-(4-Benzyloxy phonyl) 1-[(1-phenyl-

eyelobutylmethyl) carbamoyl] ethyl] methyl carbamoyl) 2 (3H imidazol 4 yl) ethyl] carbamic acid benzyl ester; or a pharmaceutically acceptable salt form thereof.

Claims 15-22 (canceled).

Claim 23 (previously added) A method of inhibiting smooth muscle proliferation in a mammal which has been subjected to injury of vascular tissue comprising administering to said mammal an amount of a compound of Claim 1 for a time and under conditions effective to sufficiently inhibit ras farnesyl transferase to inhibit said smooth muscle proliferation.

Claims 24 and 25 (canceled).